GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » GF Value Rank

Cognition Therapeutics (Cognition Therapeutics) GF Value Rank : 0 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics GF Value Rank?

Cognition Therapeutics has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Cognition Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognition Therapeutics (Cognition Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Executives
John Brendan Doyle officer: Chief Financial Officer C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Lisa Ricciardi director, officer: CEO & President C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Anthony Caggiano officer: Chief Medical Officer C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone director C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace director C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107

Cognition Therapeutics (Cognition Therapeutics) Headlines

From GuruFocus